Univariate analyses for comparisons between the modified LANZA score and each independent variable.

<p>Univariate analyses for comparisons between the modified LANZA score and each independent variable.</p

The multiple regression analysis of the independent risk factors for the factor XIII activity level depression.

<p>The results of the multiple regression analysis of the factor XIII activity levels, sex and use of tocilizumab. **<i>P</i><0.05, ***<i>P</i><0.01.</p

Pelvic computed tomography of the RA patient with factor XIII deficiency.

<p>The white arrow indicates the intra-pelvic hemorrhage. (a) Transverse plane and (b) coronal plane.</p

A comparison of the modified LANZA score based on the NSAIDs and PSL treatment status.

<p>Values are shown as the mean±SEM (standard error of the mean). Data were analyzed using Tukey-Kramer test, **p<0.01. PSL, prednisolone; NSAIDs, non-steroidal anti-inflammatory drugs.</p

Comparison of the plasma factor XIII activity levels in the healthy controls and RA patients.

<p>** the Steel-Dwass method (<i>P</i><0.01). MTX, methotrexate; TNFi, tumor necrosis factor inhibitors; TCZ, tocilizumab.</p

A comparison of the modified LANZA scores between those treated with COX-2-selective inhibitors and those treated with non-selective COX-1 and COX-2 inhibitors.

<p>(a) A comparison of the modified LANZA scores between patients treated with and without NSAIDs. (b) A comparison of the modified LANZA score between patients treated with COX-2-selective inhibitors and non-selective COX-1 and COX-2 inhibitors. Value are shown as the mean±SEM. Data were analyzed using a t-test, *p<0.05, **p<0.01. NSAIDs, non-steroidal anti-inflammatory drugs; COX, cyclooxygenase. Celecoxib, etodolac and meloxicam are COX-2-selective NSAIDs.</p

Plasma factor XIII quantitative concentrations in the RA patients treated with biologics.

<p>(a) The relationship between the factor XIII activity levels and plasma concentrations was assessed according to Pearson's correlation coefficient. (r = 0.449, <i>P</i> = 0.019). (b) Comparison of the plasma factor XIII concentrations between the RA patients treated with TNFi and those treated with tocilizumab. * Student's <i>t</i>-test (<i>P</i><0.05). TNFi, tumor necrosis factor inhibitors; TCZ, tocilizumab.</p

A multivariate analysis to determine the relationship between the modified LANZA score and independent risk factors.

<p>A multivariate analysis to determine the relationship between the modified LANZA score and independent risk factors.</p

Comparison of the baseline RA patient characteristics.

<p>Median (interquartile range (IQR)).</p>a<p>The Kruskal-Wallis test.</p>b<p>The chi-square test.</p>c<p>The Mann-Whitney U test.</p>*<p>Statistical significance (<i>P</i><0.05) was determined using the Kruskal-Wallis test for differences among the three groups. There was a significant difference between the patients treated without biologics and those treated with tocilizumab (<i>P</i><0.05), according to the Steel-Dwass method.</p>**<p>Statistical significance (<i>P</i><0.05) was calculated using the Mann-Whitney U test.</p>***<p>Statistical significance (<i>P</i><0.01) was calculated using Kruskal-Wallis test for differences among the three groups. There were significant differences between the patients treated without biologics and those treated with tocilizumab (<i>P</i><0.01) and between the patients treated with TNF inhibitors and those treated with tocilizumab (<i>P</i><0.01), according to the Steel-Dwass method.</p><p>MTX, methotrexate; TNF, tumor necrosis factor; RA, rheumatoid arthritis.</p

Single regression analyses between the factor XIII activity levels and the independent variables.

<p>Spearman's rank correlation coefficients between the factor XIII activity levels and the other variables.</p><p>d We inserted “0” as a parameters for the patients treated without methotrexate.</p>*<p>P<0.10, ***P<0.01.</p